Retinal Drusen
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
In Case You Missed: The Promise of Tyrosine Kinase Inhibitors in the Treatment of Retinal Disease
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
Woman presents for second opinion regarding medication use
A 32-year-old woman was referred by the rheumatology service for a second opinion regarding high-risk medication use evaluation.
Six biomarkers predict AMD progression with greater certainty than ‘large drusen’ sign
Researchers have identified biomarkers that predict age-related macular degeneration progression as well as biomarkers associated with progression to geographic atrophy and neovascularization, according to a review published in Ophthalmology Retina.
Autofluorescence shows two pathways to geographic atrophy
Geographic atrophy could involve two separate disease pathways, one with soft drusen and one with subretinal drusenoid deposits, according to a study published in Eye.
Top headlines in AMD/Retina: AI and the retina; imaging devices for screening; and more
In this edition, digital imaging and AI advance investigation of systemic disease through the retina; handheld retinal imaging devices may have utility in screening; Xipere launches in the US; and more.